| Oct 17 |
Poseida Therapeutics Announces Nomination of New CAR-T Development Candidate Under Collaboration with Roche
|
| Oct 15 |
MaxCyte Appoints Cynthia Collins to its Board of Directors
|
| Oct 3 |
Poseida Therapeutics Named to Newsweek's List of the Top 200 America's Most Loved Workplaces for 2024
|
| Sep 30 |
Poseida: Interim P-BCMA-ALLO1 Data Bodes Well For Phase 1B Advancement
|
| Sep 27 |
Poseida struggles post market after phase 1 multiple myeloma CAR-T therapy data
|
| Sep 27 |
Poseida Therapeutics Reports Positive Interim Phase 1 Results for Allogeneic CAR-T Therapy P-BCMA-ALLO1 with High Overall Response Rates in Heavily Pretreated Relapsed/Refractory Multiple Myeloma Patients
|
| Sep 17 |
FDA grants RMAT to Poseida’s CAR-T cell therapy P-BCMA-ALLO1
|
| Sep 16 |
Poseida Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for P-BCMA-ALLO1 to Treat Relapsed/Refractory Multiple Myeloma
|
| Sep 9 |
Poseida Therapeutics: An Underappreciated Company Continuing To Shape Up Well In 2024
|
| Sep 5 |
Poseida Therapeutics to Present New Clinical Data from Phase 1 Study of Allogeneic CAR-T P-BCMA-ALLO1 in Patients with Relapsed/Refractory Multiple Myeloma at 21st International Myeloma Society Annual Meeting
|
